We are live on ! Find out more
SCM

Sarissa Capital Management Portfolio holdings

AUM $158M
1-Year Est. Return 103.7%
This Fund
S&P 500
This Quarter Est. Return
+19.27%
1 Year Est. Return
+103.7%
3 Year Est. Return
+58.62%
5 Year Est. Return
+92.85%
10 Year Est. Return
+667.68%
AUM
$1.26B
AUM Growth
+$214M
Cap. Flow
+$41.3M
Cap. Flow %
3.29%
Top 10 Hldgs %
99.85%
Holding
14
New
–
Increased
1
Reduced
1
Closed
–

Top Buys

Rank Stock Value
1
ALKS icon
Alkermes
ALKS
+$87.2M

Top Sells

Rank Stock Value
1
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$45.9M

Sector Composition

Rank Sector Weight
1 Healthcare 99.6%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALKS icon
1
Alkermes
ALKS
$8.22B
$291M 23.14%
11,870,000
+3,920,000
+49% +$87.2M
BIIB icon
2
Biogen
BIIB
$30B
$223M 17.7%
643,000
– –
IRWD icon
3
Ironwood Pharmaceuticals
IRWD
$696M
$211M 16.77%
16,390,000
– –
GILD icon
4
Gilead Sciences
GILD
$162B
$186M 14.77%
2,697,400
– –
ALXN
5
DELISTED
Alexion Pharmaceuticals
ALXN
$119M 9.5%
650,440
– –
INVA icon
6
Innoviva
INVA
$1.55B
$86M 6.84%
6,414,000
– –
BCRX icon
7
BioCryst Pharmaceuticals
BCRX
$2.28B
$67.4M 5.36%
4,261,000
-3,376,700
-44% -$45.9M
MRSN
8
DELISTED
Mersana Therapeutics
MRSN
$54.4M 4.33%
160,224
– –
VOR icon
9
Vor Biopharma
VOR
$1.15B
$13.2M 1.05%
35,351
– –
SRSAW
10
DELISTED
Sarissa Capital Acquisition Corp. Warrants
SRSAW
$5M 0.4%
3,333,333
– –
RGLS
11
DELISTED
Regulus Therapeutics
RGLS
$1.51M 0.12%
185,185
– –
JAZZ icon
12
Jazz Pharmaceuticals
JAZZ
$15.9B
$177K 0.01%
1,000
– –
MRTX
13
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$161K 0.01%
1,000
– –
ICPT
14
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$18K ﹤0.01%
950
– –

Similar funds

4A
4D Advisors Redondo Beach, California $158M AUM 92.73% 1-Year Est. Return
DAM
Deepwater Asset Management Minneapolis, Minnesota $158M AUM 23.9% 1-Year Est. Return
PCP
Pantera Capital Partners San Francisco, California $158M AUM 600.89% 1-Year Est. Return
CF
CDC Financial Chicago, Illinois $157M AUM
HEM
Henson-Edgewater Management Avon, Ohio $157M AUM
SF
Seros Financial Tempe, Arizona $157M AUM 16.95% 1-Year Est. Return
AC
AlpenGlobal Capital Tahoe City, California $157M AUM
EP
Elkhorn Partners Omaha, Nebraska $157M AUM 11.91% 1-Year Est. Return

Sarissa Capital Management's Q2 2021 Portfolio in Review

As of Q2 2021, Sarissa Capital Management held 14 positions worth $1.26B, up 21% from $1.04B the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Sarissa Capital Management deployed $41.3M of net new capital in Q2 2021, adding to 1 existing holding.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier.

On the sell side, the largest reduction was BioCryst Pharmaceuticals, an estimated $45.9M trimmed.

  • Sarissa Capital Management added most to Alkermes in Q2 2021, an estimated $87.2M increase.
  • Sarissa Capital Management's biggest Q2 2021 reduction was BioCryst Pharmaceuticals, cutting an estimated $45.9M.
  • Sarissa Capital Management's ten largest holdings make up 100% of its $1.26B portfolio in Q2 2021.
  • Sarissa Capital Management opened 0 new positions and closed 0 in Q2 2021.
  • Sarissa Capital Management's portfolio value rose 21% quarter-over-quarter to $1.26B.

Based on Sarissa Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.